Cipla has reported that the United States Food and Drug Administration (USFDA) conducted a follow-up inspection at its manufacturing facility in Pithampur, India. The inspection, held from August 17 to August 25, 2026, resulted in seven (7) observations on Form 483. Cipla has committed to working closely with the USFDA to address these observations comprehensively and within the stipulated time.
USFDA Follow-Up Inspection Completed
Cipla Limited announced today the completion of a follow-up inspection by the United States Food and Drug Administration (USFDA) at its key manufacturing facility located in Pithampur, India. The inspection specifically focused on current Good Manufacturing Practices (cGMP).
Inspection Details and Outcomes
The USFDA inspection took place from August 17, 2026, to August 25, 2026. Upon conclusion, the Company was issued a Form 483, detailing seven (7) inspectional observations. These observations represent areas identified by the USFDA that require attention and corrective action.
Company’s Commitment to Remediation
Cipla has stated its commitment to addressing each of the received observations thoroughly and efficiently. The company plans to work in close collaboration with the USFDA to ensure all issues are resolved within the timeframe specified by the regulatory body. This proactive approach aims to maintain compliance and uphold the highest manufacturing standards.
Source: BSE
